Investors’ sentiment increased to 2.43 in Q1 2019. It’s up 1.16, from 1.27 in 2018Q4. It increased, as 7 investors sold BioCryst Pharmaceuticals, Inc. shares while 21 reduced holdings. 26 funds opened positions while 42 raised stakes. 93.65 million Shares or 0.54% less from 94.16 million shares in 2018Q4 were reported.
Bancorporation of Montreal Can invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). 125,307 were reported by Arrow mark Colorado Lc. Financial Bank of America Corp De stated it has 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Rhumbline Advisers invested in 149,535 shares. Citadel Advsr Lc reported 0.01% stake. Franklin Street Advsr Inc. Nc invested 0.07% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Quantitative Systematic Strategies Limited Company invested in 0.02% or 10,972 shares. Dekabank Deutsche Girozentrale invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Fmr Ltd Liability Com, Massachusetts-based fund reported 3.47M shares. Eam Investors Limited invested in 0.57% or 287,805 shares.
Since December 18, 2018, it had 2 insider purchases, and 6 sales for $349,992 activity. $155,299 worth of stock was sold by Sheridan William P on Tuesday, December 18. Powell Lynne had sold 2,000 shares worth $18,800 on Friday, January 18. The insider STAAB THOMAS R II sold 5,000 shares worth $49,250.
The stock of BioCryst Pharmaceuticals, Inc. (NSDAQ: BCRX) is a huge mover today! The stock decreased 4.68% or $0.1775 during the last trading session, reaching $3.6125. About 1.01M shares traded. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 31.78% since June 11, 2018 and is up trending. It has outperformed by 27.35% the S&P500.
The move comes after 6 months negative chart setup for the $398.51M company. It was reported on Jun, 11 by Barchart.com. We have $3.32 PT which if reached, will make NASDAQ:BCRX worth $31.88 million less.
Analysts await BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report earnings on August, 6. They expect $-0.31 EPS, down 63.16 % or $0.12 from last year’s $-0.19 per share.